Globus Medical to Acquire Nevro Corp. in All-Cash Transaction for $250M.

Globus Medical, a musculoskeletal solutions company, has entered into a definitive agreement to acquire Nevro Corp., a medical device company that specializes in treating chronic pain, for $250 million in an all-cash transaction. The acquisition aims to expand treatment options for patients and was unanimously approved by both companies' boards of directors. Globus Medical will acquire all shares of Nevro for $5.85 per share.

The musculoskeletal solutions company, Globus Medical (Globus), has recently announced its intention to acquire Nevro Corp. (Nevro), a medical device specialist focused on chronic pain treatment, for approximately $250 million in an all-cash transaction [1]. This strategic move, which has been unanimously approved by both companies' boards of directors, aims to broaden Globus' treatment offerings and enhance its position in the neuromodulation market.

Nevro, founded in 2003, is well-known for its innovative technologies in chronic pain treatment. Its flagship product, the HFX spinal cord stimulation (SCS) platform, has received FDA approval for the treatment of chronic pain in the leg or back, as well as diabetic neuropathy [1]. The company's acquisition of Vyrsa Technologies in late 2023 further expanded its portfolio with a range of FDA-cleared sacroiliac joint fusion devices [1].

The addition of Nevro's technologies to Globus' existing offerings is expected to create significant synergies. Globus' expertise in imaging technologies could enhance Nevro's product development and market penetration, while Nevro's neuromodulation and enabling technologies could complement Globus' existing implant solutions [1].

Moreover, Globus' existing SI joint offering, which has shown potential for growth, could benefit from Nevro's innovative technologies. The Nevro1 SI Joint Fusion System, a posterior integrated transfixation cage designed to offer enhanced stability, minimized bone removal, and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system, could provide a valuable addition to Globus' product line [1].

Studies conducted on the Nevro1 system have shown promising results, particularly in osteopenic bone. Late 2024 data indicated that Nevro1 performed equivalently in osteopenic bone when compared to a lateral triangular rod system in healthy bone [1]. This data not only validates the effectiveness of Nevro1 but also highlights its potential to address a broader range of patient needs.

Despite some investor skepticism, this acquisition is considered a relatively low-risk move for Globus. The total equity value of approximately $250 million represents a small fraction of Globus' market capitalization, and the acquisition could potentially yield significant upside through increased market penetration and enhanced product offerings [1].

In conclusion, Globus Medical's acquisition of Nevro Corp. is a strategic move that aims to expand treatment options for chronic pain patients, enhance Globus' position in the neuromodulation market, and create valuable synergies between the two companies. With its innovative technologies and promising market potential, Nevro is expected to contribute significantly to Globus' growth and success in the future.

References:
[1] "Globus Medical to Acquire Nevro." OrthoWorld, 13 Jan. 2025, https://www.orthoworld.com/globus-medical-to-acquire-nevro/